Accenture’s Growth Recalibration Sparks 16-Point Analyst Target Collapse

Accenture shares halved from July 2025 peak as weak bookings and trimmed guidance trigger a 30% drop in Wall Street's average price target in one month.

The brutal arithmetic on Accenture has become almost mechanical: every fresh set of quarterly figures brings a lower revenue forecast, and now a cascade of Wall Street rating changes has slashed the average price target by nearly 30% in just one month. The stock has shed roughly half its value since the July 2025 peak of €259.25, tumbling to around €112 – a decline that accelerated to 18% in the past week alone.

The trigger was Accenture’s fiscal third-quarter report on 18 June, which on the surface looked solid. Revenue climbed 6% to $18.72bn, operating margin edged up 20 basis points to 17.0%, and adjusted earnings per share rose 9% to $3.80. The pain came from the forward outlook: full-year growth guidance was trimmed to 3–4% in local currency from the prior range of 3–5%, while the Q4 revenue forecast of $17.75bn to $18.4bn fell short of the consensus $18.47bn. New bookings of $19.32bn – down 2% year-on-year, or 3% on a currency-adjusted basis – underscored the reluctance of corporate clients to commit to discretionary IT projects.

Within 48 hours, no fewer than six investment banks rushed to lower their targets. The most dramatic cuts came from DA Davidson ($275 to $175), Royal Bank of Canada ($253 to $175), and Truist ($210 to $150). TD Cowen went a step further by downgrading the stock to Hold and slashing its target from $258 to $150. Mizuho kept its Outperform rating but trimmed to $226 from $280, while Susquehanna set the lowest of the batch at $140. Morgan Stanley, which was not in the first wave, pushed its target to $130. The net effect: the average target across 28 Wall Street analysts collapsed to $196.85 from $274.50 a month earlier – a swing that reflects a fundamental re-evaluation of Accenture’s growth trajectory, not just a tactical tweak.

The technical picture offers no comfort. At roughly €112, the stock trades about 25% below its 50-day moving average and more than 40% below its 200-day line. The relative strength index sits at 24.9, deep in oversold territory, yet no sustained bounce has materialised. The 52-week high of €259.25 now looks like a distant memory.

Accenture can point to a resilient balance sheet to defend its valuation. Free cash flow for the full year is expected between $10.8bn and $11.5bn, and the adjusted EPS forecast of $13.78 to $13.90 implies underlying profitability is intact. The company has also been pushing into artificial intelligence, recently announcing a broad partnership with Adobe to build AI-driven customer experiences for large enterprises. But strategy alone has not been enough to calm investors, who want to see rising bookings convert the AI narrative into hard revenue growth.

The broader macroeconomic backdrop – uncertain corporate spending, especially in consulting – means Accenture’s recovery depends on the fourth-quarter results expected in September 2026. Until then, the "Moderate Buy" consensus still stands formally, but the weight of those 16 downgraded targets in a single month suggests the selling pressure will not ease unless the bookings pipeline shows a clear inflection.